Content about Certolizumab pegol

October 18, 2013

The Food and Drug Administration has approved a drug made by UCB for treating a form of arthritis.

ATLANTA — The Food and Drug Administration has approved a drug made by UCB for treating a form of arthritis.

The drug maker said Friday that the FDA had approved Cimzia (certolizumab pegol) for adults with active ankylosing spondylitis, though it declined to approve the drug for axial spondyloarthritis, or axSpA. UCB said it was working with the agency to determine how to get the drug approved for axSpA.

September 30, 2013

The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday.

BRUSSELS — The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday.

UCB announced the approval of Cimzia (certolizumab pegol) for psoriatic arthritis in adults. Psoriatic arthritis is an inflammatory, autoimmune condition that causes pain, swelling and stiffness around the joints, usually combined with the skin lesions of psoriasis. The drug was already approved to treat rheumatoid arthritis and Crohn's disease.

May 11, 2011

Patients with moderate to severe rheumatoid arthritis who respond to 12 weeks of treatment with a drug made by UCB are more likely to show improvement in their condition in the long run, according to results of a study published in the Journal of Rheumatology.

BRUSSELS — Patients with moderate to severe rheumatoid arthritis who respond to 12 weeks of treatment with a drug made by UCB are more likely to show improvement in their condition in the long run, according to results of a study published in the Journal of Rheumatology.